Head to Head Comparison: Calithera Biosciences (CALA) vs. The Competition
Calithera Biosciences (NASDAQ: CALA) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Calithera Biosciences to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
71.9% of Calithera Biosciences shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.3% of Calithera Biosciences shares are owned by insiders. Comparatively, 16.3% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Calithera Biosciences has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500. Comparatively, Calithera Biosciences’ peers have a beta of 6.66, meaning that their average share price is 566% more volatile than the S&P 500.
Earnings and Valuation
This table compares Calithera Biosciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Calithera Biosciences||$11.45 million||-$29.12 million||-13.97|
|Calithera Biosciences Competitors||$261.64 million||$67.77 million||-6.95|
Calithera Biosciences’ peers have higher revenue and earnings than Calithera Biosciences. Calithera Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Calithera Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Calithera Biosciences Competitors||-5,536.49%||-454.28%||-42.57%|
This is a breakdown of recent ratings and target prices for Calithera Biosciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Calithera Biosciences Competitors||753||3008||11116||225||2.72|
Calithera Biosciences currently has a consensus price target of $14.40, indicating a potential downside of 18.18%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.38%. Given Calithera Biosciences’ peers higher possible upside, analysts plainly believe Calithera Biosciences has less favorable growth aspects than its peers.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company’s lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.